How Should the FDA Review Diagnostic Radiopharmaceuticals?
نویسندگان
چکیده
منابع مشابه
Therapeutic and diagnostic radiopharmaceuticals#
Medical application of ionizing radiation and radioactive isotopes were considered almost immediately after their discovery. The intense research interest in radioactivity, materials structure, subatomic particles and in the establishment of physical principles resulted in milestone inventions such as the radiotracer principle, particle accelerators, nuclear reactors and detectors sensitive eno...
متن کامل“How should we treat older patients with Metastatic Colorectal Cancer, A Review”
Nearly 50 % of newly diagnosed colorectal cancer, affect people over 70 years of age. Inclusion of older patients in clinical trials has been extremely rare. As a result, there is debate on how to manage these patients because it is still unclear how to balance the therapeutic advantages and toxicities. For patients who do not have comorbid conditions, with performance status (P.S.) 0–1, treatm...
متن کاملHow Should Peer-Review Panels Behave?
Many governments wish to assess the quality of their universities. A prominent example is the UK’s new Research Excellence Framework (REF) 2014. In the REF, peer-review panels will be provided with information on publications and citations. This paper suggests a way in which panels could choose the weights to attach to these two indicators. The analysis draws in an intuitive way on the concept ...
متن کاملThe FDA should test the safety of ECT machines ∗
Electroconvulsive therapy (ECT) and the machines that deliver it have never been tested for safety and efficacy in order to receive approval from the FDA. The American Psychiatric Association and ECT advocates protested when the FDA took steps to classify the machines as posing “an unreasonable risk of illness or injury”, which would have required their testing before approval. Without requirin...
متن کاملHow Have User Fees Affected the FDA?
Some policy experts answer that question by arguing that budget constraints contributed to regulatory delays in the past. The reform simply relaxed those constraints by increasing the resources for new-drug review. However, there is little empirical evidence to suggest that changes in the fda’s budget influenced regulatory delays and the speed of review prior to user fees. Other policy experts ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Nuclear Medicine
سال: 2017
ISSN: 0161-5505,2159-662X
DOI: 10.2967/jnumed.117.200337